"Breakthrough Postpartum Depression Pill Nears Approval"

A pill called Zuranolone has shown promising results in clinical trials for treating postpartum depression (PPD) and could be approved by the FDA as early as next week. The medication, taken for two weeks, targets GABA receptors in the brain using a substance called neurosteroid. In a study of 196 mothers with PPD, those taking Zuranolone experienced significant improvements in depressive symptoms compared to those on a placebo. Side effects were minimal, but long-term effects and impact on breastfeeding remain unknown. If approved, Zuranolone would be the first pill specifically for PPD, as the only current treatment is administered through an IV.